While mycosis fungoides (MF) is typically an indolent malignancy, it may infrequently undertake an aggressive course. We used proteomic analyses to identify a biomarker 
(HSPA1A), ATP-depending RNA helicase (DDX17) and the α-isoform of laminaassociated polypeptide 2 (TMPO) had higher expression in aggressive disease versus non-aggressive. Moreover, PARP-1 was overexpressed in patients with early stage of MF who developed later an aggressive disease. PARP-1 was evaluated as a new target for therapy, demonstrating the selective dose-dependent cytotoxic effect of PARP inhibitors on Sézary cells in comparison with non-malignant lymphocytes. In conclusion, we believe that PARP-1 may serve not only as a biomarker at initial biopsies for a disease that may become aggressive but also as a new therapeutic target of advanced MF and Sézary syndrome.
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| BACKGROUND
Cutaneous T-cell lymphoma (CTCL) is a clonal malignancy that is derived from cutaneous mature T lymphocytes. Mycosis fungoides (MF) and Sezary syndrome (SzS, a leukaemic variant of CTCL) are the most common types of CTCL with no cure. The median survival of patients with stage IV disease is 18 months, even in the context of multiple lines of therapy. [1] With no method currently available to predict aggressive behaviour, treating MF that runs the aggressive course involves frequent clinical monitoring and expensive work up which could be reduced by early screening approaches.
The utilization of targeted proteomics in MF was due to the prior difficulty in working with formalin-fixed-paraffin-embedded (FFPE) samples and recovering the proteins from them. Innovative work by Hood et al [2] and others have shown the ability to utilize FFPE tissue samples in proteomics-based analyses with the nearly equivalent recovery of peptides from FFPE tissue and fresh-frozen tissue. [2, 3] We have performed global proteomic studies of patient samples from non-aggressive and aggressive MF to identify biomarkers of aggressive MF in patients from early-stage biopsy tissues.
| QUESTIONS ADDRESSED
Is Poly [ADP-ribose] polymerase 1 (PARP-1) a biomarker of advanced MF? May PARP-1 serve as a target for therapy of CTCL?
| EXPERIMENTAL DESIGN
Patients from the Cutaneous Lymphoma Clinic of the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) were selected. Global proteomic analysis [2, 3] of non-aggressive and aggressive MF patient samples was performed to determine the biomarkers of aggressive MF in patients with early-stage biopsy tissues. FFPE specimens from patients of each group underwent laser microdissection to isolate malignant T cells for proteomic analysis. For Luminex analysis, the peripheral blood was collected and data analysis was performed using four-parametric curve fitting. [4] Cleaved PARP-1 (Asp214) was analysed by xMap ™ technology. [5] A minimum of six doses of AZD2461 was used to establish the IC50 for incubated Sezary cells.
| RESULTS
A retrospective analysis was used to identify patients whose MF had an aggressive or non-aggressive course. The aggressive disease was defined as a patient's overall survival at least twice less than expected based on published data by Kim et al [1] Comparison through proteomic analysis of proteins present in non-aggressive and aggressive disease identified several differences in protein expression ( Figure 1A ). The following proteins including PARP-1, heat-shock protein family A (Hsp70) member 1 like (HSAP1L), Hsp70 member 1A
(HSPA1A), ATP-depending RNA helicase (DDX17) and the α-isoform of lamina-associated polypeptide 2 (TMPO) were increased in aggressive disease samples vs non-aggressive ( Figure 1B ). PARP-1 is a nuclear protein involved in regulating DNA damage and has been observed to have multiple roles in several cancers. [6] PARP-1 has also been found to be an important protein in the BRCA mutations of ovarian cancers. [7] Using immunohistochemistry, we compared the Figure 1C,D) . Although MF, in general, demonstrated increased expression of PARP-1 compared to normal skin throughout this study, there was a large difference in expression seen on IHC when comparing non-aggressive and aggressive MF. This is not uncommon to PARP-1, as there is evidence in other studies that increased expression in malignant cells of other cancers is related to a worse prognosis. [6] We MFI in non-malignant lymphocytes, P < .05) ( Figure 2D ). Several PARP inhibitors (PARPi) have been developed and are currently in use as treatment options for ovarian cancers. [7] Their effectiveness for these cancers is primarily due to their ability to affect the repair of DNA strand breaks. [6] There is also evidence of PARPi having effectiveness in other haematologic malignancies such as leukaemia. [6, 8] PARPi have not been specifically tested for benefit in MF. We tested the use of PARPi in Sézary syndrome by co-incubating Sézary cells with AZD2461 ( Figure 2E ). The IC50 for AZD2461 was 7.2 nmol/L (95% confidence interval = 3.8-9.7) for Sézary cells vs 16.7 nmol/L (95% confidence interval = 10.4-21.5) for control lymphocytes (P < .05).
| CONCLUSION
In this study, we applied novel techniques to perform the first proteomic analysis of biomarkers of aggressive disease in MF.
We have demonstrated that PARP-1 has increased expression in an early-stage disease that will become aggressive, compared to an early-stage disease that will not follow an aggressive disease 
